guest ::
| Home > Publications database > Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. > print |
| Home > Publications database > Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. > print |
| 001 | 277474 | ||
| 005 | 20240229155018.0 | ||
| 024 | 7 | _ | |a 10.1016/j.radonc.2023.109806 |2 doi |
| 024 | 7 | _ | |a pmid:37437607 |2 pmid |
| 024 | 7 | _ | |a 0167-8140 |2 ISSN |
| 024 | 7 | _ | |a 1879-0887 |2 ISSN |
| 024 | 7 | _ | |a altmetric:151214273 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-01395 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Jandu, Harkeran K |b 0 |
| 245 | _ | _ | |a Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2023 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1693478895_10459 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 187, October 2023, 109806Radiotherapy and Oncology |
| 520 | _ | _ | |a Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be tailored accordingly. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity two years following whole breast radiotherapy.A genome-wide association study (GWAS) was performed in 1,640 breast cancer patients with complete SNP, clinical, treatment and toxicity data, recruited across 18 European and US centres into the prospective REQUITE cohort study. Toxicity data (CTCAE v4.0) were collected at baseline, end of radiotherapy, and annual follow-up. A total of 7,097,340 SNPs were tested for association with the residuals of toxicity endpoints, adjusted for clinical, treatment co-variates and population substructure.Quantile-quantile plots showed more associations with toxicity above the p<5 x 10-5 level than expected by chance. Eight SNPs reached genome-wide significance. Nipple retraction grade≥2 was associated with the rs188287402 variant (p=2.80 x 10-8), breast oedema grade≥2 with rs12657177 (p=1.12 x 10-10), rs75912034 (p= 1.12 x 10-10), rs145328458 (p=1.06 x 10-9) and rs61966612 (p=1.23 x 10-9), induration grade≥2 with rs77311050 (p=2.54 x 10-8) and rs34063419 (p=1.21 × 10-8), and arm lymphoedema grade≥1 with rs643644 (p=3.54 x 10-8). Heritability estimates across different endpoints ranged from 25% to 39%. Our study did not replicate previously reported SNPs associated with breast radiation toxicity at the pre-specified significance level.This GWAS for long-term breast radiation toxicity provides further evidence for significant association of common SNPs with distinct toxicity endpoints. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Breast Cancer |2 Other |
| 650 | _ | 7 | |a Genome-wide association study |2 Other |
| 650 | _ | 7 | |a Late radiotherapy side effects |2 Other |
| 650 | _ | 7 | |a Radiogenomics |2 Other |
| 650 | _ | 7 | |a Radiotherapy |2 Other |
| 650 | _ | 7 | |a late toxicity |2 Other |
| 700 | 1 | _ | |a Veal, Colin D |b 1 |
| 700 | 1 | _ | |a Fachal, Laura |b 2 |
| 700 | 1 | _ | |a Luccarini, Craig |b 3 |
| 700 | 1 | _ | |a Aguado-Barrera, Miguel E |b 4 |
| 700 | 1 | _ | |a Altabas, Manuel |b 5 |
| 700 | 1 | _ | |a Azria, David |b 6 |
| 700 | 1 | _ | |a Baten, Adinda |b 7 |
| 700 | 1 | _ | |a Bourgier, Celine |b 8 |
| 700 | 1 | _ | |a Bultijnck, Renée |b 9 |
| 700 | 1 | _ | |a Colciago, Riccardo R |b 10 |
| 700 | 1 | _ | |a Farcy-Jacquet, Marie-Pierre |b 11 |
| 700 | 1 | _ | |a Chang-Claude, Jenny |0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |b 12 |u dkfz |
| 700 | 1 | _ | |a Choudhury, Ananya |b 13 |
| 700 | 1 | _ | |a Dunning, Alison |b 14 |
| 700 | 1 | _ | |a Elliott, Rebecca M |b 15 |
| 700 | 1 | _ | |a Green, Sheryl |b 16 |
| 700 | 1 | _ | |a Gutiérrez-Enríquez, Sara |b 17 |
| 700 | 1 | _ | |a Herskind, Carsten |b 18 |
| 700 | 1 | _ | |a Lambrecht, Maarten |b 19 |
| 700 | 1 | _ | |a Monten, Christel |b 20 |
| 700 | 1 | _ | |a Rancati, Tiziana |b 21 |
| 700 | 1 | _ | |a Reyes, Victoria |b 22 |
| 700 | 1 | _ | |a Rosenstein, Barry S |b 23 |
| 700 | 1 | _ | |a De Ruysscher, Dirk |b 24 |
| 700 | 1 | _ | |a Carmen De Santis, Maria |b 25 |
| 700 | 1 | _ | |a Seibold, Petra |0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215 |b 26 |u dkfz |
| 700 | 1 | _ | |a Sperk, Elena |b 27 |
| 700 | 1 | _ | |a Veldwijk, Marlon |b 28 |
| 700 | 1 | _ | |a Paul Symonds, R. |b 29 |
| 700 | 1 | _ | |a Stobart, Hilary |b 30 |
| 700 | 1 | _ | |a Taboada-Valladares, Begoña |b 31 |
| 700 | 1 | _ | |a Vega, Ana |b 32 |
| 700 | 1 | _ | |a Veldeman, Liv |b 33 |
| 700 | 1 | _ | |a Webb, Adam J |b 34 |
| 700 | 1 | _ | |a Weltens, Caroline |b 35 |
| 700 | 1 | _ | |a West, Catharine M |b 36 |
| 700 | 1 | _ | |a Rattay, Tim |b 37 |
| 700 | 1 | _ | |a Talbot, Christopher J |b 38 |
| 700 | 1 | _ | |a consortium, REQUITE |b 39 |e Collaboration Author |
| 773 | _ | _ | |a 10.1016/j.radonc.2023.109806 |g p. 109806 - |0 PERI:(DE-600)1500707-8 |p 109806 |t Radiotherapy and oncology |v 187 |y 2023 |x 0167-8140 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:277474 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-29 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOTHER ONCOL : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b RADIOTHER ONCOL : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|